Drugs / Laquinimod
Laquinimod
also known as
ABR-215062 · ABR-215062 FREE ACID · ABR-215062 SODIUM · LAQUINIMOD SODIUM · Laquinimod sodium salt · Nerventra · TV-5600 · TV-5600 FREE ACID
Small molecule targets BAX via inhibition
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Nerventra | — | 2014-08-19 | europa.eu ↗ |
Trials 16 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00349193 Comparator | Mar 2005 → Jun 2006 | relapsing-remitting multiple sclerosis | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Press releases naming this drug 40 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-05-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Announce CONCERTO trial of Laquinimod in RRMS Did Not Meet Primary Endpoint tevapharm.com ↗ |
| 2016-01-04 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials tevapharm.com ↗ |
| 2015-06-25 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial tevapharm.com ↗ |
| 2015-04-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS tevapharm.com ↗ |
| 2014-11-04 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington’s Disease Trial tevapharm.com ↗ |
| 2014-09-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting tevapharm.com ↗ |
| 2014-05-23 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech to Continue with the Development of Nerventra® (Laquinimod) for Multiple Sclerosis Following Confirmation of CHMP Opinion tevapharm.com ↗ |
| 2014-01-24 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Remain Committed to the Development of NERVENTRA® (laquinimod) for Multiple Sclerosis Following the Negative Opinion from the EMA’s CHMP tevapharm.com ↗ |
| 2013-10-04 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Presented at 29th ECTRIMS Congress Reinforce the Clinical Profile of Investigational Laquinimod on Disease Progression and Inflammation in Relapsing-Remitting Multiple Sclerosis tevapharm.com ↗ |
| 2013-10-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Newly Published Phase III Exploratory Analysis Suggests Investigational Oral Laquinimod for Multiple Sclerosis May Reduce Brain Damage Caused by Neurodegeneration tevapharm.com ↗ |
| 2013-06-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Report Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis tevapharm.com ↗ |
| 2013-03-21 | Teva Branded Pharmaceutical Products R&D, Inc. | Early versus Delayed Treatment with Laquinimod Demonstrated Significant Reduction in Risk of Disability Progression – Results of Three-Year ALLEGRO Study in Relapsing-Remitting Multiple Sclerosis tevapharm.com ↗ |
| 2013-03-06 | Teva Branded Pharmaceutical Products R&D, Inc. | First Patient Enrolled in Third Phase III Study of Oral Laquinimod for Relapsing-Remitting Multiple Sclerosis tevapharm.com ↗ |
| 2012-10-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase IIa Laquinimod Trial Results Show Positive Data for Potential Use in Active Crohn's Disease tevapharm.com ↗ |
| 2012-08-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis tevapharm.com ↗ |
| 2012-03-15 | Teva Branded Pharmaceutical Products R&D, Inc. | Phase III Study of Teva's Oral Laquinimod Published in the New England Journal of Medicine Demonstrates Clinical Benefits for Multiple Sclerosis Patients tevapharm.com ↗ |
| 2011-10-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS tevapharm.com ↗ |
| 2011-10-14 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data on Teva's Copaxone® and Laquinimod to Be Highlighted at ECTRIMS/ACTRIMS tevapharm.com ↗ |
| 2011-08-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Results of Phase III BRAVO Trial Reinforce Unique Profile of Laquinimod for Multiple Sclerosis Treatment tevapharm.com ↗ |
| 2011-04-27 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Evaluating Laquinimod for the Treatment of Multiple Sclerosis Demonstrate Neuroprotective Effects tevapharm.com ↗ |
| 2011-04-11 | Teva Branded Pharmaceutical Products R&D, Inc. | Oral Laquinimod for Multiple Sclerosis Treatment Significantly Reduced Disease Activity and Disability Progression While Providing Good Safety and Tolerability tevapharm.com ↗ |
| 2011-04-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Webcast on Results from Phase III ALLEGRO Study of Oral Laquinimod in Multiple Sclerosis tevapharm.com ↗ |
| 2010-12-09 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Successful Results of Phase III Study with Oral Laquinimod For Multiple Sclerosis tevapharm.com ↗ |
| 2010-10-15 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Evaluating Laquinimod for the Treatment of Multiple Sclerosis Demonstrate Neuroprotective Effects tevapharm.com ↗ |
| 2010-10-06 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva to Present New Data on Copaxone® and laquinimod at the 26th Annual ECTRIMS Congress tevapharm.com ↗ |
| 2010-09-20 | Teva Branded Pharmaceutical Products R&D, Inc. | Oral Laquinimod Demonstrated Sustained Efficacy and Safety in Patients with Multiple Sclerosis tevapharm.com ↗ |
| 2010-04-15 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Suggest Oral Laquinimod May Confer Neuroprotection in Addition to Immunomodulation in the Treatment of Multiple Sclerosis tevapharm.com ↗ |
| 2010-02-08 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Acquires Marketing Rights For Oral Laquinimod In The Nordic And Baltic Regions tevapharm.com ↗ |
| 2009-04-28 | Teva Branded Pharmaceutical Products R&D, Inc. | New Data Illustrate Novel Mechanism of Action of Laquinimod, An Oral Compound For The Treatment of Multiple Sclerosis tevapharm.com ↗ |
| 2009-02-12 | Teva Branded Pharmaceutical Products R&D, Inc. | Oral Laquinimod for Multiple Sclerosis Granted Fast Track Status by FDA tevapharm.com ↗ |
| 2008-11-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Completes Enrollment in Laquinimod Phase III Clinical Trial tevapharm.com ↗ |
| 2008-09-18 | Teva Branded Pharmaceutical Products R&D, Inc. | Laquinimod Demonstrated Significant and Sustained Impact on Multiple Sclerosis Disease Activity tevapharm.com ↗ |
| 2008-07-16 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Enrolls Patients for a Second Large Global Phase III Trial Of Oral Laquinimod tevapharm.com ↗ |
| 2007-11-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Initiation Of Enrollment In Pivotal Phase III Clinical Study Of Oral Laquinimod For Relapsing-Remitting Multiple Sclerosis tevapharm.com ↗ |
| 2007-06-07 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva And Active Biotech To Initiate Pivotal Phase III Trial Program Of Oral Laquinimod For Relapsing Multiple Sclerosis tevapharm.com ↗ |
| 2007-05-01 | Teva Branded Pharmaceutical Products R&D, Inc. | Laquinimod, A Novel Oral Compound, Showed Significant Reduction In Disease Activity In Patients With Relapsing - Remitting Multiple Sclerosis (RRMS) tevapharm.com ↗ |
| 2006-09-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Laquinimod Phase IIb Trial confirms efficacy and favorable safety profile and shows significant reduction in the rate of inflammatory disease activity tevapharm.com ↗ |
| 2005-06-28 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva And Active Biotech Announce The Submission Of An Ind To The Fda For Laquinimod, An Oral Product For The Treatment Of Relapsing Ms tevapharm.com ↗ |
| 2005-03-22 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva and Active Biotech Announce That Laquinimod Phase II Data Has Been Published Today in Neurology tevapharm.com ↗ |
| 2004-06-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva And Active Biotech Announce Agreement For Laquinimod Potential Oral Therapy For Multiple Sclerosis tevapharm.com ↗ |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Laquinimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01404117 ↗ |
| Known as | ABR-215062 | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Known as | ABR-215062 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Known as | ABR-215062 SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Known as | LAQUINIMOD SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Known as | Laquinimod sodium salt | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Known as | Nerventra | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Known as | TV-5600 | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Known as | TV-5600 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL66092 ↗ |
| Action | Inhibit | “laquinimod reduces the expression of Bax” PMID 27296315 ↗ Jun 2016 |
| Modality | Small molecule | — CHEMBL66092 ↗ |
| Route | Oral | “oral daily 0.3 and 0.6 mg laquinimod” PMID 18572078 ↗ Jun 2008 |
| Target | BAX | “laquinimod reduces the expression of Bax” PMID 27296315 ↗ Jun 2016 |